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No ﬁeld method exists for identifying asymptomatic individuals in areas where Leishmania infantum is
endemic. This work reports that, 24 h after stimulating whole blood with soluble Leishmania antigen
(SLA), plasma interferon-g (IFN-g) and interleukin-2 (IL-2) become signiﬁcantly elevated in samples from
asymptomatic individuals (n¼ 47) compared with those from negative controls (n¼ 50), all of them
recruited from a blood bank. When compared with the reference test SLA-lymphoproliferative assay, IL-2
appears as a new, 100% sensitive and speciﬁc marker for asymptomatic individuals with a positive
cellular response (compared with 100% and 84.78%, respectively, for IFN-g). Further studies in other
transmission areas and in other cohorts of exposed people need to be performed to conﬁrm these results.
Once validated, IFN-g and IL-2 levels in SLA-stimulated whole blood could be reliably used in the ﬁeld to
estimate the prevalence of those asymptomatic individuals with Leishmania-speciﬁc cellular immune
responses. A.V. Ibarra-Meneses, CMI 2016;22:739.e1e739.e4
© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asymptomatic individuals must be identiﬁed if the true preva-
lence of Leishmania infantum infection in endemic areas is to be
known (different studies report 25%e80%) [1] and if the potential
for such persons to act as disease reservoirs is to be understood.
The Leishmania skin test can be used in the ﬁeld to study the
prevalence of infection, but its side effects, and suspect quality in
manufacturing, have seen it banned in some countries [2,3]. The
good agreement between Leishmania skin test reactivity and the
results of the in vitro peripheral blood mononuclear cell prolifera-
tion assay (CPA) involving soluble Leishmania antigen (SLA), high-
lights the latter’s value as a detector of immune reactivity [4].
However, CPA is laborious and time-consuming; a simpler ﬁeld test
for identifying asymptomatic persons is required.ud Carlos III, Centro Nacional
for Leishmaniasis, Ctra.
adrid), Spain.
r Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).Commercial whole blood interferon-g (IFN-g) release assays
(IGRA) for assessing cell-mediated immunity against cytomegalo-
virus and Mycobacterium tuberculosis may provide the basis for a
ﬁeld test for detecting cellular responses against Leishmania spp.
[5,6]. The present work investigates the SLA stimulation of whole
blood from cured persons, those with active disease, and asymp-
tomatic individuals, following an outbreak of leishmaniasis caused
by L. infantum in Fuenlabrada (Madrid, Spain). SLA-stimulated
plasma IFN-g concentrations were recorded, as were those of
tumour necrosis factor-a (TNF-a), interleukin-10 (IL-10) and IL-2.
The aim was to establish a simple method for detecting asymp-
tomatic persons in areas where L. infantum is endemic.
Materials and methods
This study was approved by the Hospital de Fuenlabrada
(Madrid) Ethics and Research Committee; all participants gave
their consent to be involved. Blood was collected at the hospital
blood bank (330 consecutive blood donors) and internal medicine
department (36 participants) between January and December 2015.of Clinical Microbiology and Infectious Diseases. This is an open access article under
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mononuclear cells were isolated from whole blood and resus-
pended in RPMI-1640 supplemented with 10% fetal calf serum, and
cultivated with SLA for 5 days [7]. Of the blood bank samples, 47
were CPA-positive (stimulation index 2.27); the participants
providing these samples were therefore asymptomatic and their
blood was selected for analysis. Of the 283 CPA-negative samples,
50 participants were randomly selected as negative controls for
analysis (simple random sample). Eighteen of the 36 samples
collected at the medical department were from patients with active
visceral leishmaniasis (VL), and the other 18 were from cured VL
patients who attended the hospital 3 months after amphotericin B
treatment as outpatients for a medical check up (Table 1).
To search for markers of asymptomatic infection, whole blood
samples were stimulated with SLA as previously described [8,9].
For each sample, an aliquot of blood (500 mL) was placed on its own
in a tube (negative control), and another in a tube containing
10 mg/L SLA, and both were incubated at 37C for 24 h. They were
then centrifuged, the plasma was collected, and their IFN-g, TNF-a,
IL-10 and IL-2 concentrations were determined using the Cyto-
metric Bead Array Human Soluble Protein Flex Set (Becton Dick-
inson, Franklin Lakes, NJ, USA). Results for each cytokine were
expressed as the difference between the SLA-stimulated and con-
trol plasma concentrations.
A nested PCR targeting the small subunit ribosomal RNA (SSU
rRNA) genes was performed with DNA isolated from 2 mL of blood
from the 330 donor participants by acid guanidinium thio-
cyanateephenolechloroform extraction, as described previously
[10].
Data were analysed using the ManneWhitney U test. Signiﬁcance
was set at p0.05. The ability of the cytokines to detect asymptomatic
participantswas determined bycalculating the area under the receiver
operating characteristic curve (AUC) and the 95% CI.
Results
Stimulation of whole blood with SLA was associated with
signiﬁcantly higher plasma IFN-g concentrations in patients with
cured VL (especially) and asymptomatic participants compared
with negative controls (Fig. 1a: median 343.80 pg/mL with 95% CI
156.40e692.80, and 72.85 pg/mL with 95% CI 45.98e110.70,
respectively, versus 0 pg/mL). Similar ﬁndings were recorded for
TNF-a (Fig. 1b: median 64.50 pg/mL with 95% CI 34.29e247.50 and
16.75 pg/ml with 95% CI 9.76e25.30 for cured VL and asymptomatic
individuals, respectively, and below detectable levels for the con-
trol group). The patients with active VL returned the highest IL-10
concentrations; no IL-10 was detected in the plasma of asymp-
tomatic participants (Fig. 1c: median 13.70 pg/mL with 95% CI
5.75e53.40 versus 0 pg/mL). Interleukin-2was also increased in the
SLA-stimulated plasma of the cured VL and (especially)Table 1












Female 7 11 7 20
Male 11 36 11 30
Age, median (years) 41.5 42.0 42.0 42.0
CPA positive: 18 47 0 0
CPA negative: 0 0 18 50
CPA, cell proliferation assay; VL, visceral leishmaniasis.asymptomatic participants compared with negative controls
(Fig. 1d: median 86.55 pg/mL with 95% CI 13.86e168.80 and
171.00 pg/mL with 95% CI 133.40e261.40, respectively, versus 0 pg/
mL). Interestingly, no IL-2 was detected in the plasma of patients
with active VL. No Leishmania DNA was detected in any blood
sample from any asymptomatic or negative controls.
In the detection of asymptomatic participants, the AUC for IFN-g
was 0.99 (95% CI 0.98e1.00; p <0.0001), sensitivity was 100% (95%
CI 0.90e1.00), speciﬁcity was 84.78% (95% CI 0.71e0.94), and the
cut-off was 27.77 pg/mL (Fig. 1e). Importantly, the AUC for IL-2 was
1.00 (95% CI 1.00e1.00; p <0.0001), sensitivity was 100% (95% CI
0.90e1.00), speciﬁcity was 100% (95% CI 0.92e1.00), and the cut-off
was 50.37 pg/mL (Fig. 1f). TNF-a and IL-10 showed AUC of 0.85 (95%
CI 0.77e0.94) and 0.52 (95% CI 0.39e0.64), respectively.
The calculated cut-offs show that SLA-induced plasma IFN-g
identiﬁed 83% of the asymptomatic participants (39/47). However,
SLA-induced plasma IL-2 detected 100% of these individuals (47/
47).
Discussion
The present results show that plasma IL-2 in SLA-stimulated
whole blood become signiﬁcantly elevated in samples from cured
VL and asymptomatic individuals compared with those from
negative controls, and no IL-2 was detected in active VL. Interest-
ingly, IL-2 was able to detect all asymptomatic individuals with
Leishmania-speciﬁc cellular immune responses, whereas IFN-g
detected 83% of them. We have also found that the increased
expression of plasma IFN-g in SLA-stimulated whole blood distin-
guishes between cured VL/active VL/asymptomatic and uninfected
persons living in an area where L. infantum is endemic. Similar
results were described in the three studies that have evaluated
IGRAs in areas where Leishmania donovani is endemic [8,11,12]. The
present results also show TNF-a production to be increased in SLA-
stimulated plasma from cured VL, active VL and asymptomatic in-
dividuals, a ﬁnding not seen in previous studies involving
L. donovani asymptomatic subjects [11,12]. However, this increased
TNF-a production did not properly discriminate asymptomatic
participants. High IL-10 concentrations were also seen in the SLA-
stimulated blood of some patients with active VL; in these in-
dividuals the only studied T helper type 1 cytokine not detected
was IL-2. Although plasma IFN-g, TNF-a and IL-2 were increased in
whole blood samples from the asymptomatic individuals, IL-2 was
the most sensitive and speciﬁc marker for identifying this sub-
population with positive SLA-lymphoproliferative response; this is
the ﬁrst time this has been described with respect to leishmaniasis.
Our group recently described a strong correlation between SLA-
stimulated plasma IFN-g and IL-2 in individuals from the same
areawho had undergone solid organ transplant (and therefore took
immunosuppressants) [9], but the potential for IL-2 and IFN-g to
detect asymptomatic individuals was not evaluated in that work.
IL-2 has also been proposed as a marker to distinguish between
individuals with active tuberculosis, latent tuberculosis infection
and healthy controls following whole blood stimulation with
mycobacterial antigens [13e15].
In areas where leishmaniasis is endemic, the history of active VL
and treatment would be necessary to assess an asymptomatic in-
dividual, because a clear-cut deﬁnition for SLA-stimulated plasma
IL-2 concentrations could not be established when comparing
cured and asymptomatic individuals. But before considering IL-2 as
an alternative or adjunct marker to identify asymptomatic in-
dividuals, other transmission areas with lower prevalence, or
L. donovani infection, and other cohorts (malnourished, co-infected
with helminths, etc.) of exposed people must be tested. An addi-
tional limitation of this study is the need for an independent
Fig. 1. Cytokine production in whole blood in response to soluble Leishmania antigen (SLA) stimulation for 24 h. (aed) Production of (a) interferon-g (IFN-g), (b) tumour necrosis
factor-a (TNF-a), (c) interleukin-10 (IL-10) and (d) IL-2 in plasma following 24 h of SLA stimulation of whole blood from patients with cured visceral leishmaniasis (VL) patients
(CVL; n¼ 18), asymptomatic participants (Asympt; n¼ 47), patients with active disease (VL; n¼ 18), and negative controls (NVL; n¼ 50). Horizontal bars represent the mean
concentration for each cytokine. Data were analysed using the ManneWhitney U test. *p 0.05, **p 0.01, ***p 0.001, ****p 0.0001. (e,f) Receiver operating characteristic curve
analysis to determine the sensitivity and speciﬁcity of IFN-g and IL-2 to detect asymptomatic participants.
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and its true speciﬁcity lies between 92% and 100%. Furthermore, it
would be interesting to see long-term follow-up studies on
whether a subgroup of asymptomatic individuals would develop
disease and how immunological markers would evolve in such
cases. Finally, it is important to highlight that those asymptomatic
participants without speciﬁc cellular immune response will not be
detected with this marker, and molecular tools, such as PCR, should
be used in combination to avoid a risk of case under-estimation.
In conclusion, SLA-stimulated plasma IFN-g and IL-2 concen-
trations would appear to be a promising new way of detecting
Leishmania infection in individuals with speciﬁc cellular response;
it may even have the potential to replace the Leishmania skin test.
Once validated in other transmission areas and cohorts, IL-2may be
regarded as a newmarker for identifying asymptomatic status with
better speciﬁcity than IFN-g. A combination of these markers and
other molecular techniques like PCR might be used to better deﬁne
the prevalence of the asymptomatic condition, which would be
useful when taking decisions designed to control L. infantum. This
non-invasive and non-sensitizing simple assay of blood stimula-
tion, in which the cytokine concentration can be measured by
ELISA, is easily translatable to the ﬁeld. In fact, a transversal pro-
spective study to assess the accuracy of this tool (involving a large
number of samples and different transmission areas) is underway.
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